What is Vilon (Lys-Glu), does it work, and what's the real evidence?

The short answer

Vilon is a synthetic dipeptide — just two amino acids, lysine and glutamic acid (Lys-Glu, also called the "KE peptide") — from the Khavinson family of short-peptide bioregulators. It's promoted as an immune-restoring, anti-aging agent, and there's a real (if niche) body of research behind it. But that research is overwhelmingly Russian, mostly animal and in-vitro, with essentially no Western human trials — so the evidence is intriguing, not established.

Evidence tier: Mostly Tier 3–4. The gene-expression and cell-aging effects come from real peer-reviewed studies, but they're predominantly Russian-group, preclinical (rodent + cell-culture), and not independently replicated in Western human RCTs. This is education, not medical advice.

The key points:

• A 2-amino-acid dipeptide (Lys-Glu) — one of the smallest "peptide bioregulators"
• Immune/thymic lean — positioned as a thymus-restoring, immunomodulatory peptide
• Real but limited evidence — Russian, mostly animal/in-vitro; gene-expression and anti-apoptotic effects
• No Western human trials — longevity and immune claims outrun the controlled human data

For the broader category, see our longevity pillar; for the most-discussed cousin, see Epitalon.

What is Vilon?

Evidence tier: 2 — established chemistry and origin.

Vilon is a synthetic dipeptide, Lys-Glu — two amino acids, which makes it one of the shortest molecules in the entire "peptide bioregulator" class. It belongs to the family of short peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson lineage began with peptide extracts of animal organs (the thymus extract Thymalin, the pineal extract Epithalamin); researchers then identified the short active sequences within them and synthesized them as defined di-, tri-, and tetrapeptides. Vilon (Lys-Glu) is the synthetic short-peptide associated with the thymus/immune arm of that work — broadly, the immune-system counterpart to the pineal-derived Epitalon.

Because it's a defined two-amino-acid sequence rather than a complex extract, Vilon is cheap to synthesize and chemically simple. That simplicity is part of its appeal and part of the skepticism: it's hard for some scientists to accept that a bare dipeptide could have meaningful gene-level effects, while the Khavinson group argues that's precisely what short peptides do. Understanding that debate is the key to reading Vilon honestly — the chemistry is real and simple; the mechanism claims are where the controversy lives.

The "peptide bioregulator" theory — what's actually being claimed?

Evidence tier: 3 — a real but not-yet-mainstream mechanistic model.

The Khavinson framework makes a specific, ambitious claim: that these ultra-short peptides can enter cells, reach the nucleus, bind directly to DNA (or to specific promoter regions), and modulate the expression of particular genes — effectively acting as epigenetic "regulators" that restore more youthful patterns of gene activity in aging tissue. In this model, each short peptide is somewhat tissue-selective (Vilon toward immune/thymic function, Epitalon toward the pineal/telomere axis, and so on), reflecting the organ extract it was derived from.

This is genuinely interesting and supported by some mechanistic data (below), but it sits outside the mainstream Western pharmacology consensus, which is cautious about how a free dipeptide would survive, enter cells, and achieve sequence-specific DNA binding at physiological doses. The honest framing is that the bioregulator theory is a real research program with real publications — not pseudoscience — but also not an established, independently-replicated mechanism. When you read Vilon claims, separate "this gene-expression change was measured in a dish" (often true) from "this rejuvenates your immune system" (an extrapolation the controlled human data doesn't yet support).

What does the evidence actually show?

Evidence tier: 3 — real studies, mostly preclinical and single-group.

There is a genuine literature, and it's worth representing accurately:

• Gene expression in aging cells: the KE (Lys-Glu) peptide increased SIRT1 expression and reduced PARP1/PARP2 expression during the aging of human mesenchymal stem cells in culture (Khavinson group, 2023) — a plausible "pro-longevity" signature, but in vitro.
• Chromatin reactivation: Vilon reactivated condensed (heterochromatin) regions in cultured lymphocytes from elderly donors (Lezhava 2004) — consistent with the "restores youthful gene activity" claim, again in cell culture.
• Anti-apoptotic effects: among the bioregulators, Vilon showed a pronounced effect inhibiting programmed cell death (peptide bioregulators inhibit apoptosis).
• Tissue/aging effects in rodents: Vilon (with epithalon) increased the activity of membrane enzymes in the intestinal lining of old rats (Khavinson 2003); the broader program reports lifespan extension and reduced tumor incidence in lab animals (geroprotector review).

Taken together, this is a coherent, mechanism-plus-animal story pointing toward immune support and geroprotection. What it is not is human clinical proof. The studies are overwhelmingly from one research tradition, the human work is limited and largely not replicated in Western RCTs, and "increased SIRT1 in a dish" or "longer-lived mice" are encouraging signals, not demonstrations that Vilon meaningfully extends healthy human life or restores a human immune system. That gap is the entire honest assessment.

Does Vilon actually affect aging and immunity in people?

Evidence tier: 3–4 — extrapolated from preclinical data.

This is the question the marketing answers confidently and the data answers cautiously. The theory (gene regulation toward youthful patterns) and the preclinical signals (rodent lifespan, anti-apoptosis, immune-cell effects) point in a pro-longevity, pro-immune direction. Some Russian clinical reports describe immune and general-health benefits in older patients, but these are generally small, methodologically limited by modern standards, and not corroborated by independent Western trials. There are no large, randomized, placebo-controlled human longevity or immune-outcome trials of Vilon.

So the honest answer is: plausible mechanism, suggestive animal data, thin and unreplicated human evidence. For someone deciding whether to use it, that means treating any human benefit as unproven and the longevity framing as hopeful extrapolation rather than fact. This is the same evidentiary situation as Epitalon and the rest of the Khavinson peptides — interesting enough to follow, not established enough to bank on — and it's why we tier these as low-evidence despite the genuine research behind them. Our evidence-tier framework explains how we weight exactly this kind of "real studies, wrong tier for confident claims" situation.

How is Vilon used and dosed?

Evidence tier: 3 — based on the bioregulator "course" model.

In the Khavinson tradition, short-peptide bioregulators are given in short courses (e.g., a daily dose for ~10–20 days, repeated periodically a couple of times a year) rather than continuously — the idea being a "reset" pulse rather than chronic dosing. Vilon has historically been used by injection (subcutaneous or intramuscular) in the Russian studies, and short peptides are also sold as oral capsules/lyophilisates in the consumer market, though oral bioavailability of a free dipeptide is an open question (covered for the category in our non-injectable peptides guide).

Two honest caveats on dosing. First, because there are no rigorous modern dose-ranging human trials, "protocols" circulating online are derived from the Russian course model and community practice, not from Western clinical dosing standards. Second, the simplicity of the molecule doesn't make the dosing well-characterized — "it's just two amino acids" is not a safety or efficacy argument. Anyone considering it is working from an under-defined protocol for an unapproved compound, which is a reason for conservatism, not confidence.

Vilon vs Epitalon and the other Khavinson peptides — how do they differ?

Evidence tier: 3 — based on the tissue-selectivity model.

Within the Khavinson family, the peptides are loosely mapped to different systems. Vilon (Lys-Glu) is the immune/thymus-leaning one — positioned for immune restoration and general geroprotection. Epitalon (Epithalon, Ala-Glu-Asp-Gly) is the pineal-derived, most-hyped member, associated with melatonin/circadian effects and the telomerase claims that drive most of the longevity buzz — see our Epitalon page. Thymalin/Thymogen are the thymus-extract and short-peptide immune agents Vilon is conceptually related to.

The practical distinction people care about: if the interest is immune/general aging, Vilon is the family member usually pointed to; if it's telomere/longevity hype specifically, that's Epitalon's territory. But this tidy mapping is itself part of the bioregulator theory — the tissue-selectivity is asserted more strongly than independent human data confirms, so don't over-read the "Vilon = immune, Epitalon = telomeres" split as established physiology. Across all of them, the evidence pattern is the same: Russian-led, preclinical-heavy, human-thin. For the longevity-stack context (where people combine these with NAD precursors and senolytics), see our NAD longevity stack and senolytic protocol guides.

Safety, sourcing, and the honest bottom-line for use

Evidence tier: 3 — limited safety data; sourcing risk is real.

On safety, the reassuring part is that the studies report low acute toxicity, and a two-amino-acid peptide is unlikely to be acutely dangerous at typical doses. The unreassuring part is that "low toxicity in rodent studies" is not a human safety profile — there's no rigorous long-term human safety data, no Western regulatory review, and the long-term consequences of repeatedly nudging gene expression (if it does that in humans) are genuinely unknown. Anyone with a cancer history should be especially cautious about agents marketed as broadly "pro-proliferative" or gene-regulating, even where animal data suggests the opposite, because the human picture is simply untested.

Sourcing is the other real risk: Vilon is an unapproved research compound, so anything you buy comes through the gray market with the usual purity, dosing-accuracy, and contamination uncertainty — verify any vendor through independent testing (our lab-testing guide and sourcing guide). Vilon has also drawn renewed attention in longevity circles recently (community discussion on X), which is worth noting as interest, not evidence. The honest bottom line for anyone considering it: this is a low-evidence, under-characterized, unapproved compound with an interesting research backstory — reasonable to find fascinating, hard to recommend with confidence, and not a substitute for the basics (sleep, exercise, and the better-evidenced longevity interventions).

Limitations

This is educational content, not medical advice.

• The evidence is overwhelmingly Russian-group, preclinical (rodent + cell-culture); independent Western replication is limited.
• No large randomized human trials of longevity or immune outcomes exist.
• The bioregulator/DNA-binding mechanism is not mainstream-established — it's a real but unconfirmed model.
• Dosing protocols are community/Russian-derived, not validated by modern clinical standards.
• It's an unapproved research compound — sourcing, purity, and long-term safety are unverified.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Vilon is a synthetic dipeptide (Lys-Glu) from the Khavinson short-peptide bioregulator family — the immune/thymus-leaning counterpart to the pineal-derived Epitalon. It has a genuine research literature behind it: gene-expression shifts toward a pro-longevity pattern, chromatin reactivation, anti-apoptotic effects, and lifespan signals in lab animals. But that evidence is almost entirely Russian-group, preclinical, and unreplicated in Western human trials, and the headline mechanism (short peptides regulating genes by binding DNA) isn't mainstream-established. Treat Vilon as an intriguing, low-evidence, unapproved compound — fascinating to follow, premature to rely on — and keep expectations calibrated to "suggestive animal data," not "proven human anti-aging."

Related on this site

• Epitalon peptide page
• Non-injectable peptides: oral, nasal & topical compared
• NAD peptides & longevity stack
• Senolytic protocol: fisetin, D+Q, FOXO4-DRI
• Longevity pillar
• Independent peptide lab testing & heavy metals
• Peptide safety and sourcing guide
• Our evidence-tier framework

References

• Khavinson VK, et al. 2023. KE peptide (Lys-Glu) regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in aging human mesenchymal stem cells. PMID 37782636 — gene-expression effects in cell aging.
• Lezhava T, et al. 2004. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. PMID 15105581 — chromatin reactivation.
• Khavinson VK, et al. 2001. Peptide bioregulators inhibit apoptosis. PMID 11276315 — anti-apoptotic effect (Vilon most pronounced).
• 2003. Effect of vilon and epithalon on activity of enzymes in the small intestine of old rats. PMID 12660839 — tissue effects in aged rodents.
• Anisimov VN, Khavinson VK. 2010/2013. Peptide bioregulators: a new class of geroprotectors — experimental results. PMID 23734519 — lifespan/carcinogenesis overview.